Kazia Therapeutics Annual Report 2021

28 Kazia Therapeutics Limited 28 Annual Report 2021 Short-term benefits Post- employment benefits Share- based payments Movement in accrued leave Non- monetary Salary & fees Cash Bonus Cash Super- annuation Options Equity- settled Total 2020 $ $ $ $ $ $ Non-Executive Directors: I Ross* 135,272 - - - - 135,272 B Carmine 75,000 - - 7,125 - 82,125 S Coffey 75,000 - - 7,125 - 82,125 Executive Directors: J Garner 473,000 180,000 23,423 62,035 206,465 944,923 Other Key Management Personnel: G Heaton 195,000 17,500 7,275 20,188 10,745 250,708 K Hill 127,875 15,000 - - 12,826 155,701 1,081,147 212,500 30,698 96,473 230,036 1,650,854 * Salary paid in UK pounds, but disclosed in Australian dollars using a conversion rate of 0.5323 The relative proportions of remuneration that are linked to performance and those that are at risk Fixed remuneration At risk - STI At risk - LTI Name 2021 2020 2021 2020 2021 2020 Non-Executive Directors: Iain Ross 51% 100% 7% - 42% - Bryce Carmine 40% 100% 10% - 50% - Steven Coffey 40% 100% 10% - 50% - Executive Directors: James Garner 59% 59% 21% 19% 20% 22% Other Key Management Personnel: Gabrielle Heaton 85% 89% 9% 7% 6% 4% Kate Hill 72% 82% 18% 10% 10% 8%